Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stattic is a small molecule inhibitor that selectively targets the SH2 domain of Signal Transducer and Activator of Transcription 3 (STAT3), preventing its dimerization and activation regardless of phosphorylation state. By blocking STAT3 activity—including phosphorylation at Y705 and S727—Stattic inhibits downstream signaling events such as nuclear translocation and transcriptional activation. This leads to reduced cell viability in STAT3-dependent tumor cells and can induce apoptosis in certain cancer cell lines. Stattic has been used primarily as a research tool to study the role of STAT3 in cancer biology[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stattic.